Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous APL-2 in Healthy Adult Subjects

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous APL-2 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Acronyms APL-CP0713-1
  • Sponsors Apellis Pharmaceuticals

Most Recent Events

  • 06 Dec 2016 Results (n=51) of APL-CP0713-1 and APL-CP1014 studies assessing safety, tolerability, pharmacokinetics and pharmacodynamics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
  • 21 Nov 2016 Data from this and another phase I trial (APL-CP1014) will be presented at the American Society of Hematology (ASH) Annual Meeting 2016, according to an Apellis Pharmaceuticals media release.
  • 23 Jun 2016 Results published in an Apellis media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top